Latest news with #eCOA
Yahoo
3 days ago
- Business
- Yahoo
Medable launches programme to enhance eCOA build capabilities in clinical trials
US-based clinical technology provider Medable has launched a programme to supply contract research organisations (CROs) with generative AI-driven, electronic clinical outcome assessment (eCOA) build capabilities in digitally enabled studies. The Partner Program runs on the company's platform and aims to enable CROs to reduce clinical trial timelines by at least 50%, providing both administrative and financial benefits. It is also designed to help CROs generate trial-specific quotes rapidly and enter trial kick-off or bid defence meetings with pre-built digital studies. The Partner Program offers CROs a choice between self-service, managed service, or a hybrid support model, with the aim to deliver higher margin services through the use of generative AI. Among the programme's features are tools for pricing, demo support for bid defence meetings, and a content library to facilitate reuse and scalability. One of its key components is access to Studio, Medable's AI-powered tool for creating, storing and reusing eCOA instruments. Studio is designed to allow CROs to build eCOA assessments and deploy trials independently, providing the flexibility they need to scale their operations. Its features include content libraries, a translational workbench, virtual scheduling capabilities, and an AI-based point-and-click builder. Medable chief customer officer Alison Holland said: 'We have created a better buyer experience for CROs while putting powerful generative AI capabilities into their hands to reduce the time to first-patient-in and ensure greater control over the trial build process. 'Medable's Partner Program also simplifies administration and delivers strategic business advantages. Sponsors will want to work with our partners to move closer to Medable's vision of a one-day study start.' Based in California, Medable offers a digital clinical trials platform that has been used in nearly 400 trials across 70 countries to date. The company recently launched a digital-first long-term follow-up model intended to reduce burdens on sites and participants in cell and gene therapy trials. "Medable launches programme to enhance eCOA build capabilities in clinical trials" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Business Wire
4 days ago
- Business
- Business Wire
Medable Launches Partner Program for Faster Clinical Trial Startup, Greater Control, and Transparent Pricing
PALO ALTO, Calif.--(BUSINESS WIRE)-- Medable Inc., a leading provider of clinical development technology, today unveiled its new Partner Program, designed to empower contract research organizations (CROs) and other partners with generative AI-driven, self-service eCOA build capabilities for digitally enabled clinical trials. Leveraging the Medable platform, the program eliminates traditional bottlenecks for CROs to accelerate timelines by 50% or more, while delivering administrative and financial benefits, including straightforward, up-front pricing. Medable's Partner Program allows CROs to choose from three models – self-service, managed-service, or a hybrid of both support options. It offers pricing tools, demo support for bid defense meetings, and a portfolio content library to enable reuse and scale. The program provides partial or full enablement to help CROs take control and drive higher margin services, leveraging GenAI to help differentiate themselves in the market. Regardless of support options, the Medable Partner Program offers CROs a better, collaborative eCOA design experience for their sponsors with real-time updates. A major advantage of Medable's Partner Program is access to Studio, Medable's AI-powered solution for building, storing, and reusing eCOA instruments. Designed with CROs in mind, Studio enables self-service eCOA builds and trial deployments, giving CROs more control and flexibility to scale operations. Non-technical staff can easily build assessments in minutes for various studies and therapeutic areas with Medable Studio's rich content libraries, translational workbench, virtual scheduling, AI-based point-and-click builder, and user-friendly interface. In addition to the technical advantages of Medable Studio licensing, Medable's Partner Program simplifies the contractual relationship with upfront, consistent, and competitive pricing, streamlined communications, and on-demand support to reduce the need for change orders. The Medable Partner Program puts CROs in control to confidently: Leverage AI and automation to build higher-quality studies faster and more efficiently; Generate study-specific quotes in seconds using a self-serve pricing calculator; and, Enter any study kick-off or bid defense meeting with a pre-built digital study, ready for instant feedback and updates. 'We have created a better buyer experience for CROs while putting powerful generative AI capabilities into their hands to reduce the time to first-patient-in and ensure greater control over the trial build process,' said Alison Holland, Medable's Chief Customer Officer. 'Medable's Partner Program also simplifies administration and delivers strategic business advantages. Sponsors will want to work with our partners to move closer to Medable's vision of a one-day study start.' Medable has deployed its software-as-a-service platform in more than 300 decentralized and digitally enhanced clinical trials in 70 countries, serving more than one million patients and research participants globally. Customers have achieved impressive results – including 90% eCOA adherence and 50% cost reductions. A Tufts CSDD study also shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI for an investment on average of $500K in Phase II and $1.5M in Phase III trials, respectively. Recently, the company launched Medable AI and Medable Studio to automatically convert outcomes assessments into fully digital eCOAs in seconds – now accessible on Google Cloud Marketplace. Today, eCOA is foundational to digitally enabled clinical trials. By leveraging Medable's AI-powered, SaaS model and new partnership efficiencies, CROs gain significant cost savings, speed, and scalability. About Medable Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Best Digital Health Solution by the Galien Foundation, Medable's platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and was listed for the second year in a row on the Inc. 5000 in 2024.
Yahoo
10-03-2025
- Business
- Yahoo
Clario Enters into Definitive Agreement to Acquire WCG's eCOA Business
Acquisition of WCG's electronic clinical outcome assessments (eCOA) business will expand Clario's scientific expertise and offerings in neuroscience PHILADELPHIA, March 10, 2025 /PRNewswire/ -- Clario, a leading provider of endpoint data solutions to the clinical trial industry, today announced they have entered into a definitive agreement to acquire the eCOA business of WCG, a leader in providing solutions that measurably improve and accelerate clinical research. Electronic clinical outcomes assessments (eCOA), in addition to paper assessments, are used to evaluate the safety and efficacy of new drugs by measuring how a clinical trial participant feels or functions. WCG's eCOA operations offer robust, full-service clinical expertise and specialized functionality, particularly in neurology, psychiatry, neuropathic pain, and rare diseases. "WCG's eCOA business has a well-earned reputation for industry-leading expertise in neuroscience. Adding their scientific and operational capabilities to expand our neuroscience capabilities in imaging and digital physiology aligns with Clario's vision to transform lives by unlocking actionable evidence," said Chris Fikry, M.D., chief executive officer, Clario. "I am excited about the long-term positive impact this will have on customers and patients." "WCG's eCOA expertise and capabilities in subjective endpoints are a strategic and complementary fit with Clario's endpoint solutions. This transaction allows WCG to focus on being a trusted partner in connecting sponsors and CROs with sites to accelerate trials through trial design, study review, site activation, and participant recruitment and retention," said Sam Srivastava, chief executive officer, WCG. "With a legacy of supporting clinical trials over more than five decades across 130 countries, we remain well-positioned to accelerate clinical research through our AI-enabled data, technology, and expertise, paving the way to bring life-saving therapies to patients, faster." Customers of both companies can expect no immediate changes to existing contracts or relationships. "This complementary acquisition will augment our offerings by expanding our scientific expertise and service delivery capabilities," said Clario EVP and General Manager of eCOA, Terry Burke. "I am delighted that we will be positioned to further enable the success of our customers and ultimately have a greater impact on patients with unmet medical needs." The transaction is subject to regulatory approvals and other customary closing conditions. Until the acquisition closes, both organizations will continue to operate as independent entities. About Clario Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for life sciences companies. We offer comprehensive evidence-generation solutions that combine medical imaging, eCOA, precision motion, cardiac solutions and respiratory endpoints. For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have been deployed over 26,000 times to support clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2012. Clario's shareholders are Astorg, Nordic Capital, Novo Holdings, and Cinven. For more information, go to or follow us on LinkedIn. About WCG WCG is a global leader of solutions that measurably improve and accelerate clinical research. Biopharmaceutical and medical device companies, contract research organizations (CROs), research institutions, and sites partner with us for our unmatched expertise, data intelligence, and purpose-built technology to make informed decisions and optimize study outcomes, while maintaining the highest standards of human participant protection. WCG raises the bar by pioneering new concepts, reimagining processes, fostering compliance and safety, and empowering those who perform clinical trials to accelerate the delivery of medical therapies and devices that improve lives. For more information, please visit or follow us on LinkedIn or X @WCGClinical. Clario Media Contact:David Malleymedia@ WCG Media Contact:Carmin Gade, PhD484.351.9959cgade@ View original content to download multimedia: SOURCE Clario Sign in to access your portfolio
Globe and Mail
18-02-2025
- Business
- Globe and Mail
E-Clinical Outcome Assessment Solutions Market: Size, Share, and Trends
"The electronic clinical outcome assessment solutions market is poised for continued expansion, driven by technological innovations, shifting regulatory policies, and the growing demand for more efficient and patient-centric clinical trial processes." The electronic clinical outcome assessment (eCOA) solutions market has witnessed substantial growth in recent years, with an increasing adoption of technology in clinical trials. Factors driving this growth include the rising prevalence of chronic diseases, the need for efficient data collection methods, and the benefits of eCOA solutions in improving patient engagement and compliance. Electronic Clinical Outcome Assessment (eCOA) Solution Market in terms of revenue was estimated to be worth $1.8 billion in 2024 and is poised to reach $3.9 billion by 2029, growing at a CAGR of 16.6% from 2024 to 2029 according to a new report by MarketsandMarkets™. The growth in the Electronic Clinical Outcome Assessment (eCOA) Solutions market is driven by rise in patient centricity, increase in incidences of chronic disorders, and growing acceptance of eCOA solutions by several pharmaceutical and biotechnology companies for data collection and its analysis. As eCOA helps enhance patient engagement by facilitating patient-reported outcomes. Moreover, the increase in demand for real-world evidence across may boost the market during the forecast period. But the increase in concerns about data breaches and privacy may pose a challenge to the Electronic Clinical Outcome Assessment (eCOA) Solutions market during the forecast period. Download an Illustrative overview: Hybrid model is the fastest growing in the Electronic Clinical Outcome Assessment (eCOA) Solutions market in 2023. Based on component, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into software, services, and wearable, mobile & other devices. The wearable, mobile & other devices segment is further categorized into bring your own device model (BYOD), Provisioned device model, and hybrid model. The hybrid model is the fastest growing in Electronic Clinical Outcome Assessment (eCOA) Solutions market in 2023 attributing to its ability to offer a balanced and flexible approach to data collection in clinical trials. The hybrid model combines elements of both Bring Your Own Device (BYOD) and Provisioned Device models, providing a versatile solution that accommodates varying preferences and trial requirements. Hybrid model gives flexibility to the participants by offering option to use their own devices or devices provided by the study, depending on their comfort and accessibility. This flexibility reduces barriers to participation, as participants can choose the mode that aligns with their technological preferences. By application, observational studies and real-world evidence generation is the fastest growing in the Electronic Clinical Outcome Assessment (eCOA) Solutions market in 2023. Based on application, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into clinical trials, observational studies and real-world evidence (RWE) generation, patient management and registries, and other applications. Among these the observational studies and real-world evidence generation is the fastest growing in the Electronic Clinical Outcome Assessment (eCOA) Solutions market in 2023 attributing to an increasing emphasis on real-world data's significance in healthcare decision-making. Moreover, the segment's growth is due to the growing acceptance of real-world evidence (RWE) by regulatory bodies, healthcare providers, and pharmaceutical companies drives. RWE is crucial for understanding a treatment's effectiveness, safety, and overall impact on patients in everyday clinical practice. Pharmaceuticals and biotechnology companies are the largest end users of the Electronic Clinical Outcome Assessment (eCOA) Solutions market in 2023. Based on end users, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), medtech companies, government organizations, research centers & academic institutes, hospitals & healthcare providers, and consulting service companies. The pharmaceutical and biotechnology companies dominated the eCOA solutions market in 2023 attributing to growth in adoption of eCOA solution across by companies. As the Electronic Clinical Outcome Assessment (eCOA) slutions helps in advancing clinical trials by streamlining and enhancing the accuracy of data collection. Moreover, eCOA also helps to ensure the integrity of clinical data, facilitating regulatory compliance and improving overall study quality. For pharmaceutical and biotechnology firms, the adoption of eCOA translates into accelerated decision-making, reduced trial timelines, and enhanced patient engagement, thus these end users are dominating the market. North America dominates the global Electronic Clinical Outcome Assessment (eCOA) Solutions market in 2023. The Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. In 2023, North America accounted for the largest share of the Electronic Clinical Outcome Assessment (eCOA) Solutions market. As this region is home to a significant number of pharmaceutical and biotechnology companies which are using eCOA solutions. These companies conduct extensive clinical trials, seeking efficient and accurate methods of data collection to meet rigorous regulatory standards. Moreover, the well-established healthcare infrastructure in North America, coupled with a high level of digital literacy among healthcare professionals, facilitates the seamless integration of eCOA technologies. Furthermore, the region's leadership in research and development, coupled with substantial investments in healthcare technology, reinforces its position at the forefront of the eCOA market. Request Sample Pages: The electronic clinical outcome assessment (eCOA) solutions market is consolidated and is dominated by key players. The major players operating in this market IQVIA (US), Medidata (US), ICON Plc (Ireland), Signant Health (US), Clario (US), Oracle Corporation (US), Medable Inc. (US), Merative (US), Parexel International (MA) Corporation (US), Climedo Health GmbH (Germany), Healthentia (Belgium), Veeva Systems (US), assisTek (US), Curebase Inc. (US), Castor (US), EvidentIQ Group GmbH (Germany), YPrime, LLC (US), Clinical Ink (US), Clinion (US), Kayentis (France), TransPerfect (US), ObvioHealth USA, Inc. (US), WCG Clinical (Germany), ClinCapture (US), and Cloudbyz (US). IQVIA HOLDINGS INC, (US) IQVIA is the leading player in the eCOA solutions market. The company's leading position in the market can be attributed to various factors, such as its robust technology and service capabilities, good client relationships, diversified service offerings, and its ability to enhance the penetration of its offerings through significant R&D expenditure and product innovation. IQVIA focuses on product launches and agreements & partnerships to sustain its market position. The company has a wide geographical presence in over 100 countries across North America, Europe, Asia, Latin America, and Africa. The company has the largest and most comprehensive collection of healthcare data across the globe, including over 1.2 billion comprehensive prescription and promotional datasets, patient records, electronic medical records, genomic datasets, and datasets from social media. Medidata (US) Medidata is one of the leading providers of cloud-based solutions for clinical trials. The company offers a comprehensive suite of eCOA solutions designed to streamline data collection and improve patient engagement in clinical research. As part of its business overview, Medidata emphasizes its commitment to revolutionizing the way clinical trials are conducted by harnessing the power of technology to enhance efficiency, accuracy, and patient-centricity. The company's strong position in the market is due to its research capabilities and innovative product portfolio. In fiscal year 2022, the company's research & development expenses increased by 15.5% from USD 949 million in 2021 to USD 1,087 million in 2022, representing 19.2% of its net sales. Medidata has offices and facilities across North America, Europe, Asia Pacific, and Latin America. These offices serve as hubs for sales, customer support, research & development, and other business functions, allowing Medidata to effectively serve customers and partners across different regions. Get 10% Free Customization on this Report: Electronic Clinical Outcome Assessment (eCOA) Solution Market - Key Benefits of Buying the Report: The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies. This report provides insights into the following pointers: Analysis of key drivers (increasing R&D expenditure for product development by medtech, and pharma-biotech companies, rising operational costs and regulatory requirements associated with clinical research studies, favorable government support and funding for clinical trials, growing prevalence of chronic diseases & subsequent increase in clinical trials, effective monitoring of clinical data, reduction in overall costs and timelines of clinical trials), restraints (lack of skilled professionals to develop and operate eCOA solutions, high implementation and maintenance cost, lack of awareness about eCOA solutions among end users), opportunities (surging eCOA adoption owing to increasing number of clinical trials in emerging economies, growing outsourcing of clinical trial processes to CROs, gradual shift from manual data interpretation to real-time data analysis, growing penetration of mobile technology in healthcare industry), and challenges (evolving regulatory landscape and compliance requirements, interoperability & integration, data security & privacy issues, resistance from traditional healthcare professionals and concerns regarding software reliability) influencing the growth of electronic clinical outcome assessment (eCOA) solutions market. Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the electronic clinical outcome assessment (eCOA) solutions market. Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of electronic clinical outcome assessment (eCOA) solutions solutions across regions. Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the electronic clinical outcome assessment (eCOA) solutions market. Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the electronic clinical outcome assessment (eCOA) solutions market.
